Neogenomics (NEO) Gross Profit (2010 - 2026)

Neogenomics (NEO) has reported Gross Profit for 17 consecutive years, with $80.9 million the latest figure, recorded in Q1 2026.

• Gross Profit for Q1 2026 came in at $80.9 million, up 10.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $321.9 million (up 8.07% YoY), and the FY2025 annual result was $314.3 million, up 8.34% from the prior year.
• Gross Profit was $80.9 million for Q1 2026 at Neogenomics, down from $83.3 million in the prior quarter.
• Over five years, Gross Profit peaked at $83.3 million in Q4 2025 and troughed at $38.2 million in Q1 2022.
• Average Gross Profit over 5 years is $65.8 million, with a median of $67.6 million recorded in 2023.
• Year-over-year, Gross Profit decreased 17.07% in 2022 and jumped 43.37% in 2023.
• Over 5 years, Gross Profit stood at $56.8 million in 2022, then climbed by 18.94% to $67.6 million in 2023, then grew by 14.31% to $77.3 million in 2024, then increased by 7.88% to $83.3 million in 2025, then dropped by 2.97% to $80.9 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $80.9 million in Q1 2026, $83.3 million in Q4 2025, and $80.4 million in Q3 2025.